Indegene's valuation reaches $700 mn; raises $200 mn from Carlyle, Brighton

 Given the wider adoption of digital initiatives within the healthcare industry, Indegene plans to use the funds to accelerate its M&A (merger and acquisition) and global expansion plans

Private equity firm Carlyle Group and Brighton Park Capital are investing $200 million in Indegene, the Bengaluru-headquartered enterprise health tech solutions provider, for a minority stake. The transaction, which is subject to customary regulatory approvals, consists of a secondary sale from existing shareholders of Indegene and a primary investment into the company. The firm did not reveal the valuation after this funding round. According to the sources, the valuation of Indegene has increased to about $700 million.

Rising competition in the global pharmaceutical market is shifting business models and driving multi-year digital transformation programs. Decisions are increasingly data-driven and leading healthcare enterprises are seeking partners with strong domain knowledge and modern technical skills as a result. Given the wider adoption of digital initiatives within the healthcare industry, Indegene plans to use the primary investment from Carlyle and Brighton Park to accelerate its M&A (merger and acquisition) and global expansion plans.

“Carlyle’s commitment to the healthcare sector with its global network and deep pharmaceutical expertise, coupled with Brighton Park’s deep experience in the technology sector and nuanced understanding of our space, makes the two firms the ideal partners, to support our company’s continued growth,” said Manish Gupta, co-founder, and CEO of Indegene. “Their collective strengths will bring significant value to Indegene as we build on the deep domain knowledge and vertical technology we have developed over the past 20 years.”

Founded in 1998 by five first-generation entrepreneurs, Indegene has emerged as the leading digital transformation partner to the global life sciences industry. It has more than 3,000 employees across North America, Europe, China, Japan and India.